Literature DB >> 11477589

Incidence of leukemia and other cancers in Down syndrome subjects in Israel.

L K Boker1, T Blumstein, S Sadetzki, O Luxenburg, I Litvak, E Akstein, B Modan.   

Abstract

Epidemiologic data have confirmed the high susceptibility of persons with Down syndrome (DS) to leukemia. The question of proneness to other kinds of cancer is still open. In this study we reassessed the incidence rates of leukemia and other malignancies in Israeli DS subjects, based on the total population. The target population consisted of all DS subjects in Israel in the period of 1948--1995. Due to incompleteness of data, the target population was not fully achieved, thus the study population was divided into 2 subgroups: subjects born in Israel between 1979 and 1995 (registry group) and currently or past-institutionalized subjects born before 1979 (institution group). The cohort was linked with the Cancer Registry, and cancer cases that had been diagnosed through December 1995 were subsequently identified. Observed incidence rates were compared with expected rates in the general population. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) were computed for each disease category. Analyses were performed separately for each subgroup of the study population. In the registry group, 7 cancer cases were observed, compared with 1.5 expected (SIR = 4.67, 95% CI 1.9--9.6), all leukemia cases. For the institution group a total of 17 cancer cases were observed, compared with 12.8 expected. These included 4 cases of leukemia (SIR = 6.90, 95% CI 1.90--17.70). An excess of gastric cancer in male subjects (SIR = 11.9, 95% CI 1.3--42.9) was also observed. Significant excess of leukemia in DS population in Israel is in accordance with previously published data. An excess of gastric cancer in DS male subjects born before 1979, which has not been reported before, should be further explored. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11477589     DOI: 10.1002/ijc.1383

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 2.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

Review 3.  Aspects of digestive tract tumors in Down syndrome: a literature review.

Authors:  Daniel Satgé; Annie J Sasco; Michel J J Vekemans; Marie-Laure Portal; Jean-François Fléjou
Journal:  Dig Dis Sci       Date:  2006-09-29       Impact factor: 3.199

4.  Cancers and immune related diseases associated with Down's syndrome: a record linkage study.

Authors:  M J Goldacre; C J Wotton; V Seagroatt; D Yeates
Journal:  Arch Dis Child       Date:  2004-11       Impact factor: 3.791

5.  A genomic approach to study down syndrome and cancer inverse comorbidity: untangling the chromosome 21.

Authors:  Jaume Forés-Martos; Raimundo Cervera-Vidal; Enrique Chirivella; Alberto Ramos-Jarero; Joan Climent
Journal:  Front Physiol       Date:  2015-02-04       Impact factor: 4.566

6.  Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.

Authors:  Linda Bühl; Thomas Abel; Florian Wolf; Max Oberste; Wilhelm Bloch; Michael Hallek; Thomas Elter; Philipp Zimmer
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

7.  Prevalence and incidence of physical health conditions in people with intellectual disability - a systematic review.

Authors:  Peiwen Liao; Claire Vajdic; Julian Trollor; Simone Reppermund
Journal:  PLoS One       Date:  2021-08-24       Impact factor: 3.240

8.  Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature.

Authors:  Xin Li; Shijiang Xing; Qiumei Dong
Journal:  Oncotarget       Date:  2017-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.